Akebia Therapeutics reported Q3 2026 financial results highlighting a 140% increase in patients using Vafseo (vadadustat), reaching approximately 11,500. Despite $14.8 million in Vafseo revenues affected by inventory reductions, positive clinical trial data (VOICE and VOCAL) demonstrated improved safety and non-inferiority to ESAs for anemia treatment in dialysis patients. The company also advanced its rare kidney disease pipeline with a Phase 2 trial for ebribafusp alfa, expecting initial data in 2027. Akebia maintains a strong cash position of $159.3 million and plans to expand Vafseo access beyond TDAPA patients in 2027.
Akebia Therapeutics' Q3 2026 results provide context for health sector activity on Pluang. Of 150 priced health-sector US stocks, 94 rose and 48 fell as of Nov 05, 2026 19:01 WIB. Notable movers include ADMA Biologics Inc at USD 12.53 with a 19.56% increase, Revolution Medicines Inc at USD 213.95 up 7.14%, and Becton Dickinson and Co at USD 194.84 down 6.86%.
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
ACM Research reported a 37% year-over-year revenue increase to $367.7 million in Q3 2026, driven by strong demand in electrochemical plating (ECP) and advanced packaging technologies. The company is expanding manufacturing capacity and global sales e...
Purple has renewed its partnership with Lucid Motors to continue providing WiFi services across Lucid's operations in Riyadh. This renewal ensures that both staff and visitors have secure and easy internet access, supporting Lucid's growing presence ...
Investec Bank Plc, acting as joint broker to SThree Plc, disclosed public dealings involving the purchase and sale of 118,333 ordinary shares each on November 4, 2026. The transactions were conducted within a price range of 295 to 304 per share. Ther...
